Research

Hormonal

Tirzepatide treatment is not significantly associated with an increased risk of pancreatitis compared to control groups (placebo, basal insulin, or GLP-1 RAs) in patients with type 2 diabetes and obesity.

If you have Type 2 Diabetes or Obesity and are considering Tirzepatide, current data from multiple clinical trials suggests it does not significantly increase your risk of pancreatitis compared to other common diabetes or weight-loss medications. This is reassuring news if you were avoiding the drug due to fears of pancreatic inflammation.

GoodRefutesHIGH confidence
When compared to all control groups consisting of basal insulin (glargine or degludec), selective GLP1-RA (dulaglutide or semaglutide once weekly), and placebo, an increased risk of pancreatitis was not found to be significantly associated with tirzepatide (RR 1.46, [95% CI] 0.59 to 3.61; I2 = 0.0%, p = 0.436).
Qingyue Zeng et al. · Frontiers in Endocrinology · 2023

Why this rating

Based on a systematic review and meta-analysis of 9 RCTs with nearly 10,000 participants, using a fixed-effects model with low heterogeneity (I2=0%).

Source

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

Qingyue Zeng et al. · Frontiers in Endocrinology · 2023

DOI 10.3389/fendo.2023.1214334

Meta-analysis · 9 studiesCited 62×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →